

INOVIQ ANNOUNCES LEADERSHIP CHANGE

Melbourne, Australia, 23 October 2026: INOVIQ Limited (ASX:IIQ) (**INOVIQ** or the **Company**), a biotechnology company developing next-generation exosome-based diagnostics and therapeutics, today announced a planned leadership transition, with the Board and current CEO, Dr Leearne Hinch, having mutually agreed that she will step down from the role on 27 October 2026.

The Chairman, Peter Gunzburg, will assume the role of Executive Chair on an interim basis receiving no additional remuneration, while the company conducts an executive search for a new CEO. The company will advise the market of an appointment in due course.

Mr Gunzburg said: *"Over the past 10 years, Leearne has made a significant contribution to INOVIQ's development. Under her leadership, the business has evolved from a single asset early-stage technology, into a company with 2 products in market, 2 products in later stage development and 1 in early development. The Board remain confident in the foundations established for INOVIQ's next phase and thanks Leearne for her leadership, commitment and valuable contributions. We wish her well in her future endeavours".*

Dr Hinch said: *"It has been a privilege to lead INOVIQ through its transformation into an exosome diagnostics and therapeutics company. I am grateful to my Executive team and colleagues for their significant contributions, and proud of what we have achieved together in advancing the business towards important development and commercialisation milestones. I am confident that INOVIQ and its team will continue to build on these strong foundations and realise the Company's significant potential."*

The company having completed its recent review, will update the market on its plans for the future at the Annual General Meeting on 25 November 2026.

Authorised for release by the INOVIQ Limited Board of Directors.

FURTHER INFORMATION

Peter Gunzburg

Chairman

E peter.gunzburg@gmail.com

M +61 412 927 773

ABOUT INOVIQ LTD

INOVIQ Ltd (ASX: IIQ) is a leader in exosome technology advancing next-generation diagnostics and therapeutics that transform cancer care. Our product portfolio includes commercial-stage exosome isolation products, a clinical-stage diagnostic for early detection of ovarian cancer, and a cutting-edge preclinical CAR-exosome therapeutic program for solid tumours. INOVIQ is shaping the future of cancer detection and treatment to improve patient outcomes. For more information on INOVIQ, visit www.inoviq.com.